DOI
https://doi.org/10.18849/ve.v10i1.701Abstract
Question
In dogs with osteoarthritis (OA), does the oral supplementation of cannabidiol (CBD) oil, compared to conventional treatment alone, improve treatment outcomes of reducing pain and improving locomotion?
Clinical bottom line
The category of research question was:
Treatment.
The number and type of study designs that were critically appraised were:
Four papers were critically reviewed. Two of the studies were prospective, randomised, placebo-controlled, double-blind, cross-over clinical trials. One trial was a prospective clinical trial. One study was a prospective, randomised, controlled, clinical trial.
Critical appraisal of the selected papers meeting the inclusion criteria collectively provide zero/weak/moderate/strong evidence in terms of their experimental design and implementation:
Weak.
The outcomes reported are summarised as follows…
The analgesic effect of CBD oil supplementation on dogs with OA, as assessed by different parameters. These parameters included pain scoring systems (Canine Brief Pain Inventory (CBPI): comprised of the Pain Severity Score and Pain Interference Score (PIS), Liverpool Osteoarthritis in Dogs (LOAD), and veterinarian assessment), activity assessments (Hudson activity scale, Activities of Daily Living (ADLs): based on Cincinnati Orthopaedic Disability Index (CODI), informal gait analysis, and objective gait analysis), and Quality of Life Index (QoL).
In view of the strength of evidence and the outcomes from the studies the following conclusion is made…
CBD oil oral supplementation displayed a significant effect of extra pain relief on top of conventional treatment of canine OA in the clinical trials based on subjective pain assessments. However, the only study that evaluated pain and activity using objective measurements did not show significant improvements between treatment groups; therefore, the evidence supporting its use as an adjuvant to conventional therapy remains weak. Further studies utilising objective measurements are needed to improve the strength of the supporting evidence for a general use of CBD oil as additional analgesia for dogs with OA.
References
Anand, U., Pacchetti, B., Anand, P. & Sodergren, M.H. (2021). Cannabis-Based Medicines and Pain: A Review of Potential Synergistic and Entourage Effects. Pain Management. 11(4), 395–403. DOI: https://doi.org/10.2217/pmt-2020-0110
Brioschi, F.A., Di Cesare, F., Gioeni, D., Rabbogliatti, V., Ferrari, F., D'Urso, E.S., Amari, M. & Ravasio, G. (2020). Oral Transmucosal Cannabidiol Oil Formulation as Part of a Multimodal Analgesic Regimen: Effects on Pain Relief and Quality of Life Improvement in Dogs Affected by Spontaneous Osteoarthritis. Animals. 10(9), 1505. DOI: https://doi.org/10.3390/ani10091505
Copas, G., Amazonas, E., Brandon, S. (2021). The Pharmacology of Cannabinoids. In: Cital, S., Kramer, K., Hughston, L., Gaynor, J.S. (eds) Cannabis Therapy in Veterinary Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-68317-7_2
Clements, D.N., Carter, S.D., Innes, J.F. & Ollier, W.E.R. (2006). Genetic basis of secondary osteoarthritis in dogs with joint dysplasia. American Journal of Veterinary Research. 67(5), 909–918. DOI: https://doi.org/10.2460/ajvr.67.5.909
Gamble, L.-J., Boesch, J.M., Frye, C.W., Schwark, W.S., Mann, S., Wolfe, L., Brown, H., Berthelsen, E.S. & Wakshlag, J.J. (2018). Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs. Frontiers in Veterinary Science. 5, 165. DOI: https://doi.org/10.3389/fvets.2018.00165
Johnston, S.A. (1997). Osteoarthritis. Joint Anatomy, Physiology, and Pathobiology. Veterinary Clinics of North America: Small Animal Practice. 27(4), 699–723. DOI: https://doi.org/10.1016/s0195-5616(97)50076-3
Johnston, S.A., McLaughlin, R.M. & Budsberg, S.C. (2008). Nonsurgical Management of Osteoarthritis in Dogs. Veterinary Clinics of North America: Small Animal Practice. 38(6), 1449–1470. DOI: https://doi.org/10.1016/j.cvsm.2008.08.001
Kathmann, M., Flau, K., Redmer, A., Tränkle, C. & Schlicker, E. (2006). Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Archives of Pharmacology. 372(5), 354–361. https://doi.org/10.1007/s00210-006-0033-x
Kogan, L., Hellyer, P. & Downing, R. (2020). The Use of Cannabidiol-Rich Hemp Oil Extract to Treat Canine Osteoarthritis-Related Pain: A Pilot Study. American Holistic Veterinary Medical Association Journal. 58, 35–45.
Landa, L., Sulcova, A. & Gbelec, P. (2016). The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review. Veterinarni Medicina. 61(3), 111–122. DOI: https://doi.org/10.17221/8762-vetmed
Laprairie, R.B., Bagher, A.M., Kelly, M.E. & Denovan-Wright, E.M. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology. 172(20), 4790–4805. DOI: https://doi.org/10.1111/bph.13250
Lascelles, B.D.X, Gaynor, J.S., Smith, E.S., Roe, S.C., Marcellin-Little, D.J., Davidson, G., Boland, E. & Carr, J. (2008). Amantadine in a Multimodal Analgesic Regimen for Alleviation of Refractory Osteoarthritis Pain in Dogs. Journal of Veterinary Internal Medicine. 22(1), 53–59. DOI: https://doi.org/10.1111/j.1939-1676.2007.0014.x
Martello, E., Bigliati, M., Adami, R., Biasibetti, E., Bisanzio, D., Meineri, G. & Bruni, N. (2022). Efficacy of a dietary supplement in dogs with osteoarthritis: A randomized placebo-controlled, double-blind clinical trial. PLoS One. 17(2), e0263971. DOI: https://doi.org/10.1371/journal.pone.0263971
Mejia, S., Duerr, F.M., Griffenhagen, G. & McGrath, S. (2021). Evaluation of the Effect of Cannabidiol on Naturally Occurring Osteoarthritis-Associated Pain: A Pilot Study in Dogs. Journal of the American Animal Hospital Association. 57(2), 81–90. DOI: https://doi.org/10.5326/jaaha-ms-7119
O'Brien, M. & McDougall, J. J. (2018). Cannabis and joints: scientific evidence for the alleviation of osteoarthritis pain by cannabinoids. Current Opinion in Pharmacology. 40, 104–109. DOI: https://doi.org/10.1016/j.coph.2018.03.012
Zou, S. & Kumar, U. (2018). Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. International Journal of Molecular Sciences. 19(3), 833. DOI: https://doi.org/10.3390/ijms19030833
License
Copyright (c) 2025 Tracy Yeung, Eduardo Uquillas
This work is licensed under a Creative Commons Attribution 4.0 International License.
Veterinary Evidence uses the Creative Commons copyright Creative Commons Attribution 4.0 International License. That means users are free to copy and redistribute the material in any medium or format. Remix, transform, and build upon the material for any purpose, even commercially - with the appropriate citation.
Most read articles by the same author(s)
- Alexandra Robinson, Tsim Christopher Sun, Eduardo Uquillas, In horses undergoing volatile anaesthesia, is recovery quality superior with sevoflurane compared to isoflurane? , Veterinary Evidence: Vol. 8 No. 1 (2023): The first issue of 2023
